

Effect of intra-ovarian platelet rich plasma in women with poor ovarian response

Abstract

Background: Poor ovarian responder (POR) women, whose ovarian response to gonadotropin stimulation has decreased, are at higher risk of unsuccessful in-vitro fertilization (IVF). Therefore, this study designed to evaluate the effect of intra-ovarian platelet rich plasma (PRP) on POR women.

Methods: This single-arm trial research was done on 20 POR women referred to the IVF Unit, university-based hospital, Tehran, Iran between October 2020 and September 2021. For all participants, autologous PRP was injected into each ovary by transvaginal ultrasound guidance under spinal anesthesia between days 12 and 14 of the menstrual cycle. After 12 weeks of PRP injection, embryo transfers were carried out following our routine IVF department protocol. The study outcomes were the number of mature oocytes, and pregnancy rates.

Results: The average age of the participants was 41.80 ± 1.82 yr. The average infertility duration was 9.70 ± 1.89 yrs., with 80% primary infertility type. After PRP injection, follicle-stimulating hormone levels dropped about 1% ($P=0.499$), anti-Mullerian hormone levels were on average 4.5% higher ($P=0.356$), and estradiol levels raised by 1.2% ($P=0.681$). The average number of oocytes and their quality increased after PRP injection, while these changes were not significant ($p\text{-value} > 0.05$). Chemical pregnancy was detected in 3 (15%) women and clinical pregnancy was detected only in one person.

Conclusion: This study revealed that PRP injection into ovaries of POR women is safe and had a tendency to improve ovarian reserve markers and serum levels of AMH, estradiol, number and quality of oocytes.

Keywords: Ovarian reserve, Assisted reproductive techniques, Pregnancy outcome, Anti-Mullerian hormone, Oocyte quality.

Citation:

Davari tanha F, Salimi Setudeh Sh, Khalaj Sereshki Z, et al. Effect of intra-ovarian platelet rich plasma in women with poor ovarian response. Caspian J Intern Med 2023; 14(3): 485-489.

Fatemeh Davari tanha (MD)¹
Shohreh Salimi Setudeh (MD)^{1*}
Mahbod Ebrahimi (MD)¹
Elham Feizabad (MD)¹
Zahra Khalaj Sereshki (MD)¹
Firoozeh Akbari Asbagh (MD)¹
Hamideh Pakniat (MD)²
Azadeh khalili (MD)¹
Zahra Kaveh³
Sara Saeedi (MD)¹

1. Department of Infertility, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran

2. Department of Obstetrics and Gynecology, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

3. Student Research Committee, Tehran University of Medical Sciences, Tehran, Iran

* Correspondence:

Shohreh Salimi Setudeh,
Department of Obstetrics and Gynecology, Yas Hospital,
1598718311, Next to Sarv St.,
Mirzai Shirazi St., North Nejat Elahi St., Karim Khan Blve.,
Tehran, Iran

E-mail:

shohreh.salimi28@gmail.com
Tel: +98 2142160863

Received: 25 Jan 2021

Revised: 27 April 2022

Accepted: 29 April 2022



© The Author(s)

Publisher: Babol University of Medical Sciences

The strategy of acquiring PRP is non-expensive and low invasive. It consists of a high concentration of platelets found in plasma originating from peripherally collected blood, which carries a large type of proteins, hormones, cytokines, and triggers cell proliferation, growth, and differentiation (10,11). Although former studies showed encouraging results about beneficial influence of PRP in infertile women with improper endometrium thickness (4), recurrent unsuccessful implantation (5), insufficient responses to ovarian stimulation (6), delaying follicle atresia, oocyte degeneration, and ovarian tissue regeneration (7) these studies are few, low sample size and controversial. Therefore, this study was designed to evaluate the effect of intra-ovarian PRP on POR women.

Methods

This single-arm trial was done on 20 women referred to the IVF Unit, university-based hospital, Tehran, Iran between October 2020 and September 2021. The Tehran University of Medical Sciences Ethics Committee (IR.TUMS.MEDICINE.REC.1399.257) approved the study and the study protocol was registered in Iranian randomized clinical trial registration (IRCT20091012002576N19). The participants signed the informed consent. Inclusion criteria included POR infertile women based on Bologna criteria (12) which are defined as advanced age (≥ 40 years), history of cycle cancelation, equal or less than 3 oocytes after conventional stimulation protocol, antral follicle count (AFC) $< 5-7$ follicles or anti-Mullerian hormone (AMH) $< 0.5-1.1$ ng/ml, as well as not no infertility causes in her partner. Women with ovarian failure because of gonadal dysgenesis/chromosomal abnormalities, history of major pelvic or abdominal surgeries or pain, anticoagulant or psychotropic drug use, psychiatric diseases, immunoglobulin A deficiency, and cancer were excluded.

For PRP preparation, the venous blood sample of the woman was taken. Then, the blood sample was centrifuged at 1200 rpm for 10 minutes. The upper two-thirds and the middle coat layer were separated from the precipitated red blood cells and centrifuged again at 3300 rpm for 6 minutes. The upper two-thirds of the resulting plasma was then separated and the remaining plasma and precipitate were homogeneous. With this method, about 6 ccs of concentrated platelets with a concentration of 900,000 per microliter were obtained, which can be stored at room temperature for 0-4 hours. After preparation of autologous PRP in the IVF laboratory, it was injected into each ovary by transvaginal ultrasound (TVS) guidance under spinal

anesthesia by one expert infertility fellowship and using needle number 17 of ovarian puncture during days 12 and 14 of the menstrual cycle.

About 12 weeks after the PRP injection, the ART was done as follows. On the second day of expected menstruation, the women were evaluated about endometrial thickness (ET) and AFC with TVS (4.5-7 MHz probe, Sono line G-40, produced with Siemens, Germany). If ET and AFC were proper, 300 micrograms of gonadotropin (CinnalF, CinnaGen Company, Iran) was prescribed. Serial TVS examinations were used to assess follicular maturation. Whenever follicle(s) $\geq 10-12$ mm in average diameter was detected, human menopausal gonadotropin (hMG) (Pooyesh Daru, Iran) and Cerotide (Cetorelix, SERPERO Company, Swiss) were added. Gonadotropin hormone-releasing hormone (GnRH) antagonist was continued until a mature oocyte by the diameter of 18 mm was observed at TVS, then 250 micrograms recombinant human chorionic gonadotropin (hCG) (Ovitrelle, Merck Serono, Italy) was injected. After 36 hours, a TVS-guided oocyte retrieval was performed under spinal anesthesia. The embryos were transferred on days 3-5 after the procedure. Ampule progesterone (Iran Hormone Company, Iran) was used at 100 mg daily for luteal phase support.

The following data were recorded for all study patients: age, marriage duration, infertility duration and type, body mass index (BMI), as well as follicle-stimulating hormone (FSH), estradiol, luteinizing hormone (LH), AMH, and AFC concentrations before and after PRP injection. The study outcomes were the number of mature oocytes, chemical pregnancy (two weeks after fetal transfer, laboratory positive beta-hCG test) rate, and clinical pregnancy (six weeks after embryo transfer, ultrasound gestational sac by transvaginal sonography) rate. All the data were analyzed through Statistical Package for the Social Sciences (SPSS) Version 24.0. A p -value < 0.05 was considered statistically significant. Independent samples t -test and non-parametric Mann-Whitney U-test was used to evaluate mean differences. A chi-square test and Fisher's exact test were applied to detect the differences in proportion.

Results

In this study, 32 infertile women were assessed for eligibility; of them, 12 women had been excluded, six due to severe azoospermia in their partners, three due to leiomyoma, and three due to decline to participate. Finally, the data of 20 women were analyzed. The average age of

the women was 41.80 ± 1.82 years. The average infertility duration was 9.70 ± 1.89 years, and 80% had primary infertility. The other demographic characteristics are shown in table 1. Women who were treated with PRP had non-significant alternation in biochemical ovarian reserve markers (table 2). After PRP injection, FSH levels dropped about 1% ($P=0.499$), AMH levels were on average 4.5%

higher ($P=0.356$), and estradiol levels raised by 1.2% ($P=0.681$). Also, the average number of oocytes and their quality increased after PRP injection, while these changes were not significant (table 3). Of the 20 participants, chemical pregnancy was detected in 3 (15%) women and clinical pregnancy was detected only in one person.

Table 1. The demographic characteristics of participants

Variables	Mean±SD	Minimum	Maximum
Female age	41.80±1.82	40	46
Body mass index	25.85±3.16	21.23	32.87
Infertility Duration	9.70±1.89	7	12
Endometrial thickness	8.00±1.25	5	9
Follicle stimulating hormone	13.65±1.14	11.0	16.0
Anti-Mullerian hormone	0.44±0.18	0.18	0.80
Estradiol	810.30±500.74	305	2516

Table 2. Biochemical ovarian reserve marker changing

Variable	PRP injection		P-value
	Before	After	
Follicle stimulating hormone	13.65	13.47	0.499
Anti-Mullerian hormone	0.44	0.47	0.356
Estradiol	810.30	820.50	0.681

PRP: platelet rich plasma

Table 3. Frequency of oocyte, embryo quality and pregnancy rate

Variables		Mean±SD	P-value
Oocyte Number	pre-PRP	4.05±1.14	0.661
	post-PRP	4.25±1.16	
Quality of the oocytes	M1	pre-PRP	0.089
		post-PRP	
	M2	pre-PRP	0.334
		post-PRP	
GV	pre-PRP	0.811	
	post-PRP		1.15±1.3
Post-PRP Embryo number		2.75±0.96	
Post-PRP Quality of the embryos	A	0.40±0.68	
	B	1.20±0.69	
	C	1.15±0.813	

PRP: platelet rich plasma

Discussion

This study showed single-dose autologous intra-ovarian PRP injections of POR women result to decrease FSH, and increase AMH, estradiol levels, number of oocytes and their quality, although these changes were not significant and did not improve the pregnancy outcomes. Our study finding was in line with Stojkowska et al.'s (13) study that showed the pregnancy and live birth rate in POR women after PRP injection did not differ significantly compared to the non-PRP group, although a tendency for improvement in ovarian reserve indices was detected after PRP injection. The possible causes for this non-significant difference might be due to the low sample size studies, low dose of PRP, and short duration follow-up.

In contrast, in Cakiroglu et al.'s study (11), following intra-ovarian autologous PRP injection in women with primary ovarian insufficiency, antral follicle improvement and spontaneously conceived was detected in 70% and 7.4% of them, respectively. Therefore, they concluded that PRP injections, as a simple approach, result in outcome improvement. In comparison to that study, our patients were older, and the quality of oocytes was less. Conversely with our findings, Melo et al.'s (14) study showed a higher FSH, AMH, and AFC levels, and pregnancy rates after PRP, the possible reason for these differences are the applied dose of PRP, which has been prescribed in three consecutive menstrual cycles in Melo et al.'s study.

The mechanism of PRP in ovarian activity resurgence attributes to increases in concentrations of PDGF, TGF- β , IGF-1/2, VEGF, and EGF which result in increasing the number and maturation of preantral follicles, as well as rising in serum level of AMH in infertile women older than 40 years with premature ovarian insufficiency (15,16). The prevalence of POR women due to cigarette smoking, inappropriate diet, and chemo and radiotherapy is increasing, and a huge number of these women are willing to have their own children without using donated oocytes (17-19).

PRP injection into the ovaries of POR women seems safe and had a tendency to improve ovarian reserve markers and serum levels of AMH, estradiol, and the number of oocytes and their quality. Hence, it should be recommended to these women with the aim of ovarian reserve improvement, especially in younger ones. Although further trials and prospective studies are needed to evaluate PRP intervention in different subjects with different doses. Despite the strong points of this study, there were some

limitations such as less sample size with no control group and randomization.

Acknowledgments

The authors thank the embryologists (Dr. Fardin Amidi and Dr. Samaneh Hosseini), and all the IVF department staff.

Funding: This research was carried out with the financial support of Tehran University of Medical Sciences.

Conflict of Interests: The authors declare no conflicts of interest.

Authors' contribution: F.D.: Design of the study; S.S.S., Z.K.S., and A.K.: Data gathering. Z.K. and S.S.: Interpretation of data. M.E., F.A. and H.P.: Drafting the manuscript; all authors approved the final version of the manuscript.

References

1. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. *Reprod Biol Endocrinol* 2015; 13: 37.
2. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. *Hum Reprod Update* 2003; 9: 61-76.
3. Oyesanya OA, Olufowobi O, Ross W, Sharif K, Afnan M. Prognosis of oocyte donation cycles: a prospective comparison of the in vitro fertilization-embryo transfer cycles of recipients who used shared oocytes versus those who used altruistic donors. *Fertil Steril* 2009; 92: 930-6.
4. Pantos K, Nitsos N, Kokkali G, et al. Ovarian rejuvenation and folliculogenesis reactivation in perimenopausal women after autologous platelet-rich plasma treatment. Centre for Human Reproduction, Genesis Athens Hospital, Chalandri-Athens, Greece; p:401. Available at: <https://sals3.patientpop.com/assets/docs/111052.pdf>
5. Sills ES, Rickers NS, Li X, Palermo GD. First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. *Gynecol Endocrinol* 2018; 34: 756-60.
6. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to

- clinical applications. *Am J Sports Med* 2009; 37: 2259–72.
7. Dawood AS, Salem HA. Current clinical applications of platelet-rich plasma in various gynecological disorders: an appraisal of theory and practice. *Clin Exp Reprod Med* 2018; 45: 67–74.
 8. Hosseini L, Shirazi A, Naderi MM, et al. Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. *Reprod Biomed Online* 2017; 35: 343–50.
 9. Szafarowska M, Jerzak M. Ovarian aging and infertility. *Ginekol Pol* 2013; 84: 298-304.
 10. Sundman EA, Cole BJ, Karas V, et al. The anti-inflammatory and matrix restorative mechanisms of platelet-rich plasma in osteoarthritis. *Am J Sports Med* 2014; 42: 35–41.
 11. Cakiroglu Y, Saltik A, Yuceturk A, et al. Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. *Aging (Albany NY)* 2020; 12: 10211-22.
 12. Ferraretti AP, Gianaroli L. The Bologna criteria for the definition of poor ovarian responders: is there a need for revision? *Hum Reprod* 2014; 29: 1842-5.
 13. Stojkowska S, Dimitrov G, Stamenkovska N, Hadzi-Lega M, Petanovski Z. Live birth rates in poor responders' group after previous treatment with autologous platelet-rich plasma and low dose ovarian stimulation compared with poor responders used only low dose ovarian stimulation before in vitro fertilization. Open access Maced J Med Sci 2019; 7: 3184-8.
 14. Melo P, Navarro C, Jones C, Coward K, Coleman L. The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study. *J Assist Reprod Genet* 2020; 37:855-63.
 15. Reddy SHR, Reddy R, Babu NC, Ashok GN. Stem-cell therapy and platelet-rich plasma in regenerative medicines: a review on pros and cons of the technologies. *J Oral Maxillofac Pathol* 2018; 22: 367–74.
 16. Jain NK, Gulati M. Platelet-rich plasma: a healing virtuoso. *Blood Res* 2016; 51: 3–5.
 17. Collins GG, Rossi BV. The impact of lifestyle modifications, diet, and vitamin supplementation on natural fertility. *Fertil Res Pract* 2015; 1: 11.
 18. Kawamura K, Cheng Y, Suzuki N, et al. Hippo signaling disruption and akt stimulation of ovarian follicles for infertility treatment. *Proc Natl Acad Sci U S A* 2013; 110: 17474–9.
 19. Suzuki N, Yoshioka N, Takae S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. *Hum Reprod* 2015; 30: 608–15.